Penumbra, Inc. ( PEN ) Nowojorska Giełda Papierów Wartościowych

Cena: 299.65 ( 1.67% )

Aktualizacja 12-05 21:54
Nowojorska Giełda Papierów Wartościowych
Branża: Medycyna - Urządzenia

Finanse
Rachunek zysków i strat
Bilans
Przepływy pieniężne
Prognozy
Statystyki
Dywidendy
Rekomendacje
Modele wyceny
Wskaźniki
Analiza techniczna

symbol 1D 5D 1M 3M 6M YTD 1Y 3Y 5Y 10Y
PEN 2.0 1.7 13.6 6.8 16.1 25.3 26.7 39.2 34.2 531.6
Notowania:

Opis firmy:

Penumbra, Inc. projektuje, rozwija, produkuje i sprzedaje urządzenia medyczne w Stanach Zjednoczonych i na arenie międzynarodowej. Firma oferuje systemy trombektomii oparte na aspiracji i urządzenia akcesoriów, w tym urządzenie rewaskularyzacyjne do mechanicznej trombektomii, takiego jak system Penumbra w ramach Penumbra Red, JET, ACE, 3D RECASCULAIIII AD I MARNY SILNIKÓW PENUMBRA, a także komponenty i akcesoria; Układy do embolizacji nerwowo -naczyniowej w leczeniu pacjentów o różnych rozmiarach tętniaków i innych zmian nerwowo -naczyniowych pod nazwami marki cewki Penumbra 400, POD400, PAC400 i Penumbra Smart Cewki; oraz systemy dostępu nerwowo -naczyniowego zaprojektowane w celu zapewnienia dostępu wewnątrzczaszkowego do stosowania w szeregu terapii nerwowo -naczyniowych pod markami neuronów, neuronów, selekcji, odniesienia, BMX96, DDC i PX. Zapewnia również neurochirurgiczne narzędzia aspiracyjne do usuwania tkanki i płynów pod marką urządzenia ewakuacyjnego Artemis Neuro; Systemy trombektomii oparte na aspiracji do zastosowań naczyniowych pod marką systemu indygo; oraz odłączane systemy cewek zatorowych do embolizacji peryferyjnej pod markami Ruby Coil i Ruby LP. Ponadto firma oferuje mikrokattewnik do dostarczania odłączanych cewek i urządzeń okluzji pod marką latarnią; oraz odłączalne, dostarczające mikrokatteczniki urządzenia okluzyjne zaprojektowane przede wszystkim do zamykania naczyń peryferyjnych pod marką POD (urządzenie okluzyjne Penumbra), a także wciągające technologie komputerowe i wciągające terapeutyki w celu promowania zdrowia, funkcji motorycznej i poznania pod względem prawdziwej marki systemu immersyjnego; oraz uzupełniające się urządzenie do użytku z cewką Ruby i Pod KUD do okluzji naczyń pod cewką pakującej i cewki pakowania LP. Firma sprzedaje swoje produkty za pośrednictwem organizacji sprzedaży bezpośredniej i dystrybutorów. Penumbra, Inc. został zarejestrowany w 2004 roku i ma siedzibę w Alameda w Kalifornii.

Informacje o spółce:
Sektor: Zdrowie
Branża: Medycyna - Urządzenia
Zatrudnienie: 4 200
Giełda: Nowojorska Giełda Papierów Wartościowych
Ilość akcji w obrocie: 96.1091
Ilość akcji: Brak danych
Debiut giełdowy: 2015-09-18
WWW: https://www.penumbrainc.com
CEO: Mr. Adam Elsesser J.D.
Adres: One Penumbra Place
Siedziba: 94502 Alameda
ISIN: US70975L1070
Wskaźniki finansowe
Kapitalizacja (USD) 11 735 077 423
Aktywa: 1 533 181 000
Cena: 299.65
Wskaźnik Altman Z-Score: 20.39
Stabilny (niskie ryzyko bankructwa)
Dywidenda: 0
P/E: 71.3
Ilość akcji w obrocie: 96%
Średni wolumen: 482 900
Ilość akcji 39 161 961
Wskaźniki finansowe
Przychody TTM 1 280 150 000
Zobowiązania: 382 250 000
Przedział 52 tyg.: 221.26 - 310.0
Piotroski F-Score:
EPS: 4.2
P/E branży: 31.0
Beta: 0.514
Raport okresowy: 2026-02-17
WWW: https://www.penumbrainc.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Maggie S. Yuen Chief Financial Officer 666 043 1972
Ms. Johanna Roberts Executive Vice President, General Counsel & Secretary 661 890 1972
Mr. Adam Elsesser Co-Founder, Chairman, President & Chief Executive Officer 601 620 1962
Dr. Arani Bose M.D. Co-Founder & Director 54 000 1962
Mr. Lambert Shiu Chief Accounting Officer 539 939 1980
Ms. Gita Barry President of Immersive Healthcare 0 0
Ms. Jee Hamlyn-Harris Investor Relations Officer 0 0
Mr. Ben Tompkins Executive Vice President of Development & Compliance 0 0
Mr. Pankaj Tiwari Executive Vice President & Chief Information Officer 0 0
Mr. Ben Sorci Executive Vice President of Operations 0 0
Lista ETF z ekspozycją na akcje Penumbra, Inc.
Symbol ETF Ilość akcji Wartość
BNDX 1 585 419 470 939
XMH.TO 1 240 840 1 307 593
IJH.AX 1 240 840 1 760 722
IJH 1 240 840 357 945 114
XUU.TO 1 240 840 706 573
XMC.TO 1 240 840 2 093 586
XAW.TO 1 240 840 446 628
VTI 1 164 771 264 833 982
VTS.AX 1 164 771 264 833 982
VB 873 192 198 537 665
BRTR 796 749 0
VBK 490 371 111 495 654
VXF 414 118 94 158 009
XMHQ 323 251 93 248 215
MDY 287 070 81 289 075
IWP 249 709 72 033 555
XMMO 226 603 65 368 167
IHI 190 691 55 008 632
SPMD 180 476 50 495 456
IWF 146 351 42 217 872
IJK 138 308 39 897 708
IWR 136 314 39 322 499
VHT 110 771 25 186 002
SCHM 102 862 29 454 820
IJJ 72 376 20 878 304
SCHG 71 727 20 200 034
IVOO 57 750 13 130 617
JQUA 57 677 16 638 084
DFAS 55 651 15 570 593
QGRO 52 922 14 807 046
SPY4.L 50 736 14 195 425
SPY4.DE 50 736 12 323 048
VONG 50 259 11 427 388
XINC.TO 47 006 1 515
XGRO.TO 47 006 248 653
XBAL.TO 47 006 120 454
XCNS.TO 47 006 9 413
XEQT.TO 47 006 868 485
ITOT 47 006 13 559 820
SCHX 39 762 11 239 570
MDYG 36 728 10 276 095
CSMD 33 939 9 790 383
FXH 30 910 4 202 142
DFAC 27 709 7 752 701
IWB 27 327 7 883 019
IUSN.DE 27 158 6 794 660
WSML.L 27 158 7 834 268
WLDS.L 27 158 5 977 546
VT 26 511 6 027 806
IVOG 22 948 5 217 686
SCHB 22 533 6 374 210
IYH 22 381 6 456 247
MDYV 22 004 6 167 289
IUSG 19 730 5 691 513
LYP2.DE 18 985 4 662 670
SP5L.L 18 985 4 100 585
SP5C.PA 18 985 4 662 670
LYSPH.SW 18 985 4 342 111
LSPU.L 18 985 5 374 379
LSPX.L 18 985 410 058 514
6TVM.DE 18 985 4 662 670
SP5C.L 18 985 5 374 379
SP5H.PA 18 985 4 662 670
SPHC.MI 18 985 4 662 670
ETFSP500.WA 18 985 19 754 100
LYPS.DE 18 985 4 662 670
SP5G.L 18 985 4 100 585
JMEE 18 973 5 473 141
JHMM 17 654 4 998 730
BBMC 17 482 5 043 032
FNDA 16 872 4 867 115
FSMD 15 705 3 947 765
FHLC 15 513 3 899 502
USVM 14 778 4 263 009
CUS1.L 14 170 3 118 853
CSUSS.MI 14 170 3 545 192
CUSS.L 14 170 4 087 619
SXRG.DE 14 170 3 545 192
ESML 13 822 3 987 232
PINK 13 062 3 767 995
TMSL 12 879 3 603 415
PRFZ 11 652 3 361 252
IUSV 11 160 3 219 325
JMOM 11 112 3 205 478
IVOV 10 976 2 495 613
SMMD 10 759 3 103 648
ISCG 10 664 3 076 244
IWV 10 660 3 075 090
VT 10 198 3 029
DFUS 9 850 2 755 931
VISM.AX 8 765 3 044 219
XHE 8 698 2 471 014
HTEC 8 260 0
ESGV 8 196 1 863 524
SMLF 7 438 2 145 639
AASI.PA 7 368 1 737 675
AASU.SW 7 368 2 002 914
AASG.L 7 368 152 819 891
AASU.L 7 368 2 002 914
AMEA.DE 7 368 1 737 675
SPTM 6 824 1 909 276
FNY 6 772 1 553 122
FNX 6 431 979 067
FMED 6 264 1 574 581
WOSC.L 6 115 1 306 438
WDSC.L 6 115 1 710 915
ZPRS.DE 6 115 1 485 246
VONE 6 033 1 371 723
DFAU 5 997 1 677 900
NUSC 5 635 1 621 189
UMDV.AS 5 453 1 573 026
SILJ 5 331 1 571
QVMM 5 032 1 451 581
PTMC 4 876 1 406 579
ACWI.PA 4 693 1 144 315
LYY0.DE 4 693 1 144 315
ACWU.L 4 693 1 318 983
ACWL.L 4 693 100 636 821
OMFL 4 676 1 348 885
XJH 4 638 1 337 923
VFQY 4 635 1 174 138
FFND 4 092 1 180 419
JPME 4 063 1 172 053
SCHK 2 957 835 900
SMMV 2 945 849 544
VTHR 2 909 661 419
BOUT 2 712 782 330
EZM 2 690 775 984
AVUS 2 640 738 645
MTAV.AS 2 401 692 616
EQAL 2 192 632 326
RWK 2 085 601 459
FFLS 2 050 591 363
PAMC 1 908 550 400
AGBP.L 1 897 417 485
ISCB 1 727 498 187
IYY 1 700 490 399
EUNA.DE 1 669 417 485
BFOR 1 651 476 263
PTL 1 628 469 629
ETHO 1 612 465 013
IEML.L 1 580 455 735
EMGA.L 1 580 455 735
SEML.L 1 580 347 726
SEML.MI 1 580 395 259
IUSP.DE 1 580 395 259
EPU 1 553 448 134
FAD 1 521 364 626
TILT 1 520 438 474
AGUG.AS 1 447 417 485
AGGU.L 1 447 417 485
AGGG.L 1 447 417 485
EUNU.DE 1 447 362 085
DCOR 1 380 386 110
MVV 1 347 388 569
GUSA 1 266 309 397
DFSU 810 226 629
ZPRV.DE 672 141 609
USSC.L 672 163 125
MNTL 617 149 937
SPYI.DE 600 145 731
IMID.L 600 167 874
R1GR.L 589 169 908
V3AM.L 580 100 620
V3AL.L 580 131 874
V3AB.L 580 100 620
V3AA.L 580 131 874
JHML 560 158 564
MIDU 553 154 723
AEGG.L 531 116 880
SHIR.SW 501 116 880
AEGE.MI 467 116 880
AVLC 460 128 703
GGUS 437 106 798
AGGD.AS 405 116 880
AGGE.AS 405 116 880
ONEO 386 108 002
LEER.DE 382 91 534
CEC.PA 382 91 534
SPGM 381 106 597
DEUS 344 99 233
XUH.TO 259 74 853
JDOC 245 70 675
UMDD 239 68 944
STXM 224 63 425
CBUG.DE 210 52 539
EWSA.AS 210 60 578
USFM.L 196 55 542
USUE.DE 196 55 542
HART 167 42 254
MDEV 138 44 135
FNDB 138 39 389
BMED 130 37 501
AVSU 116 32 455
STXG 105 29 730
VLU 82 22 770
MIDE 65 18 750
MMTM 53 14 828
STXE 2 0
BRTR 1 329
VEU 0 0
PZW.TO 0 19 304
IGDA.L 0 0
BINC -848 -244 522
CLSE -1 466 -422 897
Wiadomości dla Penumbra, Inc.
Tytuł Treść Źródło Aktualizacja Link
Here's Why Penumbra (PEN) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2025-05-15 14:56:16 Czytaj oryginał (ang.)
Here's Why Penumbra (PEN) is a Strong Growth Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores. zacks.com 2025-05-14 14:50:48 Czytaj oryginał (ang.)
3 Mid-Cap Medical Stocks Outperforming the Market While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance. marketbeat.com 2025-05-06 16:50:17 Czytaj oryginał (ang.)
Penumbra, Inc. to Present at the BofA Securities 2025 Health Care Conference ALAMEDA, Calif. , April 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. prnewswire.com 2025-04-29 20:30:00 Czytaj oryginał (ang.)
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst. seekingalpha.com 2025-04-29 15:45:00 Czytaj oryginał (ang.)
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2025-04-29 14:50:41 Czytaj oryginał (ang.)
3 Reasons Growth Investors Will Love Penumbra (PEN) Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com 2025-04-28 17:45:37 Czytaj oryginał (ang.)
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2025-04-28 14:50:42 Czytaj oryginał (ang.)
Penumbra Among Well-Insulated Companies From Ongoing Tariff Dynamics, Says Analyst Penumbra Inc PEN stock is trading higher after the company reported better-than-expected first-quarter 2025 earnings and reaffirmed the 2025 forecast. benzinga.com 2025-04-24 19:27:03 Czytaj oryginał (ang.)
Penumbra Q1 Earnings & Revenues Top Estimates, Stock Up, Margins Expand PEN reports better-than-expected earnings and revenues in the first quarter of 2025. zacks.com 2025-04-24 15:45:44 Czytaj oryginał (ang.)
Penumbra, Inc. (PEN) Q1 2025 Earnings Call Transcript Penumbra, Inc. (NYSE:PEN ) Q1 2025 Earnings Conference Call April 23, 2025 4:30 PM ET Company Participants Cecilia Furlong - Business Development & IR Adam Elsesser - Chairman & CEO Maggie Yuen - CFO Jason Mills - EVP, Strategy Conference Call Participants Robbie Marcus - JPMorgan Lei Huang - Wells Fargo Pito Chickering - Deutsche Bank Macauley Kilbane - William Blair Bill Plovanic - Canaccord Travis Steed - Bank of America Ryan Zimmerman - BTIG Kallum Titchmarsh - Morgan Stanley Richard Newitter - Truist Matthew O'Brien - Piper Sandler David Rescott - Baird Operator Good afternoon. My name is Tameka and I will be your conference operator today. seekingalpha.com 2025-04-24 00:15:41 Czytaj oryginał (ang.)
Penumbra (PEN) Reports Q1 Earnings: What Key Metrics Have to Say The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-04-23 23:00:39 Czytaj oryginał (ang.)
Penumbra (PEN) Q1 Earnings and Revenues Top Estimates Penumbra (PEN) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.41 per share a year ago. zacks.com 2025-04-23 22:15:33 Czytaj oryginał (ang.)
Penumbra, Inc. Reports First Quarter 2025 Financial Results ALAMEDA, Calif. , April 23, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2025. prnewswire.com 2025-04-23 20:05:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Penumbra, Inc. (NYSE: PEN) and Encourages Current Penumbra Shareholders to Contact the Firm PHILADELPHIA, April 21, 2025 (GLOBE NEWSWIRE) -- The law firm of Kaskela Law LLC is investigating Penumbra, Inc. (NYSE: PEN) on behalf of the company's current shareholders. globenewswire.com 2025-04-21 21:20:00 Czytaj oryginał (ang.)
Why Penumbra (PEN) is Poised to Beat Earnings Estimates Again Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. zacks.com 2025-04-21 17:15:41 Czytaj oryginał (ang.)
Penumbra (PEN) Earnings Expected to Grow: Should You Buy? Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com 2025-04-16 15:06:35 Czytaj oryginał (ang.)
Reasons to Retain Penumbra Stock in Your Portfolio for Now PEN continues to attract investor interest with its strong Thrombectomy business and portfolio expansion efforts. zacks.com 2025-04-08 15:00:41 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Penumbra, Inc. (NYSE: PEN) NEW YORK , April 8, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Penumbra, Inc. (NYSE: PEN) on behalf of the company's shareholders.  The investigation seeks to determine whether Penumbra's directors breached their fiduciary duties in connection with recent corporate actions. prnewswire.com 2025-04-08 12:00:00 Czytaj oryginał (ang.)
Penumbra, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for April 23, 2025 ALAMEDA, Calif. , April 3, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the first quarter 2025 after market close on Wednesday, April 23, 2025 at 4:30 PM Eastern Time. prnewswire.com 2025-04-03 20:30:00 Czytaj oryginał (ang.)
Penumbra, Inc. Announces Don Kassing will Retire from Board of Directors ALAMEDA, Calif. , Feb. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced today that after 17 years of distinguished service, Don Kassing has notified the company that he will retire from the board of directors effective April 1, 2025. prnewswire.com 2025-02-21 18:05:00 Czytaj oryginał (ang.)
Penumbra (PEN) Upgraded to Buy: Here's Why Penumbra (PEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com 2025-02-20 15:00:35 Czytaj oryginał (ang.)
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises Penumbra reports better-than-expected earnings and revenues in the fourth quarter of 2024. zacks.com 2025-02-19 10:16:11 Czytaj oryginał (ang.)
Penumbra, Inc. (PEN) Q4 2024 Earnings Call Transcript Penumbra, Inc. (NYSE:PEN ) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Larry Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Bill Plovanic - Canaccord Richard Newitter - Truist Securities Samantha Kurtz - Piper Sandler Michael Sarcone - Jefferies Ryan Zimmerman - BTIG Shagun Singh - RBC Capital Markets Michael Kratky - Leerink Partners Operator Good afternoon. My name is Rob and I will be your conference operator today. seekingalpha.com 2025-02-19 01:04:03 Czytaj oryginał (ang.)
Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. zacks.com 2025-02-18 21:01:13 Czytaj oryginał (ang.)
Penumbra (PEN) Beats Q4 Earnings and Revenue Estimates Penumbra (PEN) came out with quarterly earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $0.76 per share a year ago. zacks.com 2025-02-18 20:20:14 Czytaj oryginał (ang.)
Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results ALAMEDA, Calif. , Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024. prnewswire.com 2025-02-18 18:05:00 Czytaj oryginał (ang.)
Should You Add Penumbra Stock to Your Portfolio Right Now? PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts. zacks.com 2025-02-12 09:36:09 Czytaj oryginał (ang.)
Penumbra, Inc. Schedules Fourth Quarter and Full Year 2024 Earnings Release and Conference Call for February 18, 2025 ALAMEDA, Calif. , Jan. 21, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time. prnewswire.com 2025-01-21 18:30:00 Czytaj oryginał (ang.)
Buy 4 Low-Beta Stocks AVO, TXO, PEN & STRA to Beat Market Volatility It is imperative to build a portfolio of low-beta stocks to navigate a volatile market. AVO, TXO, PEN & STRA are well-poised to gain. zacks.com 2025-01-17 17:46:30 Czytaj oryginał (ang.)
3 Reasons Why Growth Investors Shouldn't Overlook Penumbra (PEN) Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com 2025-01-16 15:46:20 Czytaj oryginał (ang.)
5 Must-Buy Efficient Stocks to Increase Your Portfolio Returns Invest in companies like YPF, TEF, PEN, DECK and ANF to make the most of higher efficiency levels. zacks.com 2025-01-15 10:51:10 Czytaj oryginał (ang.)
Penumbra (PEN) Surges 6.3%: Is This an Indication of Further Gains? Penumbra (PEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. zacks.com 2025-01-08 08:10:24 Czytaj oryginał (ang.)
Reasons to Add Penumbra Stock to Your Portfolio Now PEN stays on investors' radars due to its strong Thrombectomy business and international growth plans. zacks.com 2025-01-07 09:55:25 Czytaj oryginał (ang.)
IART or PEN: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Instruments sector might want to consider either Integra LifeSciences (IART) or Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now? zacks.com 2025-01-06 14:46:17 Czytaj oryginał (ang.)
Penumbra, Inc. to Present at the 43rd Annual J.P. Morgan Healthcare Conference ALAMEDA, Calif. , Dec. 30, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the 43rd Annual J.P. prnewswire.com 2024-12-30 18:30:00 Czytaj oryginał (ang.)
Is Penumbra (PEN) a Solid Growth Stock? 3 Reasons to Think "Yes" Penumbra (PEN) could produce exceptional returns because of its solid growth attributes. zacks.com 2024-12-25 15:46:10 Czytaj oryginał (ang.)
Here's Why Penumbra (PEN) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-12-23 12:46:13 Czytaj oryginał (ang.)
4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2025 Investing in large-cap MedTech stocks like MCK, PEN, CAH and PEN can be profitable for investors in 2025. zacks.com 2024-12-20 12:26:08 Czytaj oryginał (ang.)
Here's Why Penumbra (PEN) is a Strong Momentum Stock The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2024-12-18 12:51:20 Czytaj oryginał (ang.)
Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst Shares of Penumbra Inc PEN recovered slightly in early trading on Tuesday, after a week of correction. benzinga.com 2024-12-17 13:03:40 Czytaj oryginał (ang.)
3 Medical Instruments Industry Stocks to Buy on the GenAI Wave MASI, PEN and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and supply issues mar their prospects. zacks.com 2024-12-16 14:16:19 Czytaj oryginał (ang.)
Penumbra (PEN) is an Incredible Growth Stock: 3 Reasons Why Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com 2024-12-09 15:46:19 Czytaj oryginał (ang.)
Why Penumbra (PEN) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. zacks.com 2024-12-06 12:50:26 Czytaj oryginał (ang.)
Is Penumbra Stock a Smart Buy for Your Portfolio Right Now? PEN stays on investors' radars due to its robust portfolio expansion and international growth plans. zacks.com 2024-12-03 10:01:20 Czytaj oryginał (ang.)
GMED vs. PEN: Which Stock Should Value Investors Buy Now? Investors interested in stocks from the Medical - Instruments sector have probably already heard of Globus Medical (GMED) and Penumbra (PEN). But which of these two stocks presents investors with the better value opportunity right now? zacks.com 2024-11-29 14:46:29 Czytaj oryginał (ang.)
Why Is Penumbra (PEN) Up 6.7% Since Last Earnings Report? Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? zacks.com 2024-11-29 14:36:41 Czytaj oryginał (ang.)
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-11-26 12:55:29 Czytaj oryginał (ang.)
3 Reasons Growth Investors Will Love Penumbra (PEN) Penumbra (PEN) possesses solid growth attributes, which could help it handily outperform the market. zacks.com 2024-11-21 15:46:10 Czytaj oryginał (ang.)
Penumbra, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference ALAMEDA, Calif. , Nov. 20, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024. prnewswire.com 2024-11-20 18:30:00 Czytaj oryginał (ang.)
Here is Why Growth Investors Should Buy Penumbra (PEN) Now Penumbra (PEN) is well positioned to outperform the market, as it exhibits above-average growth in financials. zacks.com 2024-11-05 15:46:32 Czytaj oryginał (ang.)
Here's Why Penumbra (PEN) is a Strong Momentum Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. zacks.com 2024-11-05 12:51:11 Czytaj oryginał (ang.)
New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system ALAMEDA, Calif. , Nov. 5, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra's computer assisted vacuum thrombectomy (CAVT™) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other treatment options. prnewswire.com 2024-11-05 11:00:00 Czytaj oryginał (ang.)
Penumbra Q3 Earnings Beat, Margins Expand, Stock Up in After Market The third-quarter results reflect another strong performance by Penumbra's U.S. thrombectomy business. zacks.com 2024-10-31 11:50:32 Czytaj oryginał (ang.)
Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript Penumbra, Inc. (NYSE:PEN ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman and Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Richard Newitter - Truist Securities Robert Marcus - JPMorgan Joanne Wuensch - Citi Michael Sarcone - Jefferies Samantha Kurtz - Piper Sandler Michael Kratky - Leerink Pito Chickering - Deutsche Bank Michael Matson - Needham Operator Good afternoon. My name is Jeremy, and I will be your conference operator today. seekingalpha.com 2024-10-31 01:45:27 Czytaj oryginał (ang.)